Non-motor Symptoms (Depressive Symptoms) of Parkinson's Disease and Their Course Under Pramipexole Treatment
Status:
Completed
Trial end date:
2008-04-01
Target enrollment:
Participant gender:
Summary
The objective of this PMS study is the evaluation of depressive symptoms measured with
Unified Parkinson's Disease Rating Scale (UPDRS) Part I (mentation, behavior and mood) and
with Hospital Anxiety and Depression Scale Depression Subscore (HADS-D) under pramipexole
treatment in early and advanced PD patients. In addition it will be investigated whether
improvement of depressive symptoms is linked to improvement in motor function (UPDRS Part
III). 250 patients diagnosed with Parkinson's disease (PD) will be investigated by 80
specialists (neurologists or neurologists/psychiatrists) across Austria. Pramipexole will be
taken orally at an initial dosage of 0.375 mg/day (using a three times daily schedule
independently of food intake) and can be titrated upwards, as required, at weekly intervals
to a maximum total daily dose of 4,5 mg (TID) as per Summary of Product Characteristics
(SPC).